Cas:1334499-90-9 Ethyl 5,7-difluoro-3-iodo-1H-indole-2-carboxylate manufacturer & supplier

Chemical Name:Ethyl 5,7-difluoro-3-iodo-1H-indole-2-carboxylate

CAS.NO:1334499-90-9

Synonyms:1H-Indole-2-carboxylic acid, 5,7-difluoro-3-iodo-, ethyl ester;sc1040;Ethyl 5,7-difluoro-3-iodo-1H-indole-2-carboxylate;x9858

Molecular Formula:C₁₁H₈F₂INO₂

Molecular Weight:351.088

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:401.4±40.0 °C at 760 mmHg

Density:1.9±0.1 g/cm3

Index of Refraction:1.646

PSA:42.09000

Exact Mass:350.956757

LogP:3.87

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 1H-Indole-2-carboxylic acid, 5,7-difluoro-3-iodo-, ethyl ester chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,x9858 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethyl 5,7-difluoro-3-iodo-1H-indole-2-carboxylate Use and application,x9858 technical grade,usp/ep/jp grade.

Related News: The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered. 2-mercapto-4,5-bis-(thien-2-yl)-imidazole manufacturers “The Delta variant is clearly circulating, and it’s more contagious, and it seems to be causing more disease,” said ACIP member Katherine Poehling, M.D., an epidemiologist at Wake Forest School of Medicine. 1,2,3,4-oxatriazol-5-amine hydrochloride suppliers He also mentioned that derivatives of these APIs and lot of other value-added APIs in the same range will also be manufactured at the new facility. 1-[6-fluoro-(2R)-3,4-dihydro-2H-1-benzopyran-4-one]-(1S)-1,2-ethylene glycol vendor & factory The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005.,The suit says that while BRAF kinase inhibitors existed prior to Plexxikon’s discoveries, they were not selective, and Plexxikon’s have a core molecular structure that allows them to bind selectively to kinase created by the BRAF mutation. That allows for higher doses to be administered.